Xilio Therapeutics
About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Employees: 73
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
9% more capital invested
Capital invested by funds: $12.3M [Q1] → $13.4M (+$1.07M) [Q2]
3% more funds holding
Funds holding: 30 [Q1] → 31 (+1) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
3.21% less ownership
Funds ownership: 41.54% [Q1] → 38.33% (-3.21%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Raymond James Dane Leone 75% 1-year accuracy 3 / 4 met price target | 251%upside $4 | Outperform Maintained | 8 Nov 2024 |
Financial journalist opinion
Based on 3 articles about XLO published over the past 30 days